Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Benzo fused at 4,5-positions of the diazole ring

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

514385000 - 1,3-diazoles

514393000 - Polycyclo ring system having the diazole ring as one of the cyclos

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514395000 Chalcogen or nitrogen bonded directly at 1-, 2- or 3-position of the diazole ring by nonionic bonding 22
Entries
DocumentTitleDate
20090318521Synthesis of 4-Bromomethyl-2'-Formylbiphenyl and 4-Bromomethyl-2'-Hydroxymethylbiphenyl and Its Use in Preparation of Giotensin II Antagonists - 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl are useful starting material for the preparation various angiotenzin II antagonists, which are prepared from 4-bromomethyl-2′-cyanobiphenyl or 4′-bromomethylbiphenylcarboxyilic derivatives using selected hydride reagent.12-24-2009
20100160402Bisbenzimidazoles as antimalarial agents - The present invention relates to antimalarial agents. In particular, the present invention relates to the use of bisbenzimidazoles of Formula I for the prevention and/or treatment of malaria,06-24-2010
20100076041INDOLE- AND BENZIMIDAZOLE AMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS - The use of substituted amides of structure (I) for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11 βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11 βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.03-25-2010
20130041005PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS - The present invention relates to a compound of general formula (I),02-14-2013
20130041004Liquid Formulations Of Bendamustine - Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.02-14-2013
20130041003Bendamustine Pharmaceutical Compositions - The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.02-14-2013
20090326029NON-CYCLIC SUBSTITUTED BENZIMIDAZOLE THIOPHENE BENZYL ETHER COMPOUNDS - The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.12-31-2009
20110015245BENDAMUSTINE AMPHIPHILIC CATIONIC COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic cationic compounds, which self assemble to form aggregates. The exhibiting enhanced stability in aqueous solutions, including plasma. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or with less frequent dosages or to improve its therapeutic effect while using the same as presently used treatment protocol.01-20-2011
20110015244BENDAMUSTINE AMPHIPHILIC ANIONIC COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising bendamustine and one or more amphiphilic anionic compounds and self assembled aggregates, which aggregates exhibit enhanced stability in aqueous solutions, including plasma, are disclosed. The unexpectedly enhanced stability afforded by such aggregates permits patients to be treated with bendamustine in lower and/or with less frequent dosages or to improve its therapeutic effect while using the same as presently used treatment protocol.01-20-2011
20120115918Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.05-10-2012
20080293795COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ).11-27-2008
20090062362Veterinary Formulation for Administration of a Water-Insoluble Drug to a Target Animal Through a Water Distribution System - This invention concerns a method for the preparation of a suspoemulsion formulation, which can be easily produced on an industrial scale and which allows the reproducible and effective administration of one or more water-insoluble veterinary drugs through water distribution systems. The water-insoluble veterinary drug, in finely ground form, is dispersed in a water immiscible liquid, followed by homogenisation of this system into a water phase. To facilitate the preparation of a stable formulation, one or more stabilising agents such as emulsifiers, thickeners, anti-oxidants and anti-microbials can be used. The resulting suspoemulsion shows excellent long term storage stability and a good “in use” stability after dilution in a vessel and during all handling and transport in the water distribution system.03-05-2009
20090131493SUBSTITUTED BENZIMIDAZOLES FOR TREATMENT OF HISTOMONIASIS - The present invention relates to the use of substituted benzimidazoles for controlling histomoniasis, especially in turkeys.05-21-2009
20090048321Benzimidazole Derivatives and Their Use for Modulating the GABA-Alpha Receptor Complex - This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith.02-19-2009
20090012140Preparation of Telmisartan Salts with Improved Solubility - New alkali and earth-alkali salts of telmisartan in amorphous form and a new crystalline sodium salt of telmisartan have been prepared by preparing a solution despite low solubility of telmisartan and rapidly vacuum evaporating to dryness.01-08-2009
200900992462-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 - 2-((R)-2-Methylpyrrolidin-2-yl)- I H-benzimidazole-4-carboxamide Crystalline Form 2, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.04-16-2009
20120238611DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula:09-20-2012
20090082416DEUTERIUM-ENRICHED BENDAMUSTINE - The present application describes deuterium-enriched bendamustine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20100099726INHIBITORS OF PYRUVATE KINASE AND METHODS OF TREATING DISEASE - The invention provides pharmaceutical compositions, kits, and methods of treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia using compounds that selectively inhibit pyruvate kinase M2 and an assay measuring chemical modulation of pyruvate kinase activity.04-22-2010
20120071532NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.03-22-2012
20110172281Anti-Viral Drugs for Treatment of Arenavirus Infection - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).07-14-2011
20110172280Substituted Benzimidazoles - This invention relates to novel substituted benzimidazoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound that modulates the GABA07-14-2011
20110207789METHODS RELATED TO CASEIN KINASE II (CK2) INHIBITORS AND THE USE OF PURINOSOME-DISRUPTING CK2 INHIBITORS FOR ANTI-CANCER THERAPY AGENTS - Disclosed are methods related to label-free biosensor cellular assays to classify multienzyme complex modulators in live cells. Disclosed are also methods related to the identification of purinosome disrupting Casein Kinase II (CK2) inhibitors, and methods related to the use of purinosome disrupting CK2 inhibitors as therapeutic agents for modulating CK2 activity and purine synthesis pathway, and for improving prevention and treatment of CK2 associated cancers, viral infection and inflammation conditions.08-25-2011
20080306129BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS - The present invention relates to compounds of Formula I:12-11-2008
20080312303Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex - This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith.12-18-2008
20080242716Ion Channel Modulators - The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.10-02-2008
20080221188New Benzimidazole Derivatives - Provided herein are compounds in accord with Formula I:09-11-2008
20090312384Benzimidazole As Cooling Compounds - A method of providing a cooling sensation to the skin or mucous membranes of the mouth by applying thereto a quantity of at least one chemical compound sufficient to cause a desirable degree of cooling sensation, the chemical compound comprising a compound of formula I:12-17-2009
20090264488NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.10-22-2009
20090062363AMIDE DERIVATIVE OR SALT THEREOF - [Problem] To provide a compound which can be used for the prevention and/or treatment of diseases in which 5-HT03-05-2009
20100267793METHOD OF TREATMENT USING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS - Disclosed are methods of treating a hyperproliferative disorder or a disease related to vasculogenesis or angiogenesis in a mammal, comprising administering to said mammal an effective amount of a compound of the formula10-21-2010
20120095069PHARMACEUTICAL ORAL TELMISARTAN SOLUTION - A pharmaceutical solution, preferably a drinkable pharmaceutical solution of the active substance telmisartan is described, having a pH above 10 and additionally containing one or more sugar alcohols added to improve the flavour and shelf life, wherein the sugar alcohols or the pharmaceutical solution have a maximum content of 1000 ppm of reducing sugars.04-19-2012
200900992452-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 - 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.04-16-2009
20080262063NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy,10-23-2008
20080262062METHOD OF TREATING DISEASES WITH PARP INHIBITORS - The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in a subject population with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors.10-23-2008
20090221657Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I - Compounds of Formula I, or pharmaceutically acceptable salts thereof:09-03-2009
20090170922Benzimidazole derivatives and their use as a medicament - A subject of the present application is new benzimidazole derivatives of formula07-02-2009
201301233172-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 - 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.05-16-2013
20100240724Edible Film - The present invention relates to an edible film composition comprising a waxy starch hydrolysate, a modified starch and a water-soluble polymer, and an edible film comprising the same. The present edible film may not only have an excellent film forming property, solubility and feeling in the oral cavity, but also be easily prepared at low cost, and thus be usefully used as an oral cleanser or a bad breath remover for oral cleansing, and a soluble formulation on tongue for uptake of drug in the oral cavity.09-23-2010
20100222402METHOD OF MANUFACTURING 4'-[[4-METHYL-6-(1-METHYL-1H-BENZIMIDAZOL-2-YL)-2-PROPYL-1H-BENZIMIDAZOL-- 1YL]METHYL]BIPHENYL-2-CARBOXYLIC ACID (TELMISARTAN) - A carboxylic acid of the general formula R09-02-2010
20100210701Novel Forms of Bendamustine Free Base - Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described.08-19-2010
20110034527NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.02-10-2011
20090111865Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof - Compounds of formula I or pharmaceutically acceptable salts thereof:04-30-2009
20110028527Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma - Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain with benzimidazole derivatives with PPARgamma agonist activity, as well as methods for preparing medicaments used in such treatments of mammalian pain.02-03-2011
20110034526Benzimidazole Compounds - This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) having formula (I) and related methods:02-10-2011
20110039905BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - The invention relates to compounds of formula (I)02-17-2011
20130190374GRM3 MUTATIONS AND USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF MELANOMA - Described herein is a G-protein coupled receptor (GPCR)-directed mutational analysis of tumor DNA obtained from melanoma tissue samples. The GPCR gene glutamate receptor, metabotropic 3 (GRM3) was identified as the most highly mutated GPCR gene in this screen. Functional characterization of GRM3 mutants revealed that these mutants promote activation of MEK, anchorage-independent cell growth and metastasis. Thus, provided herein are methods of diagnosing a subject as having melanoma, or susceptible to developing melanoma, by detecting the presence of at least one mutation in GRM3. Also provided are methods of treating a subject with melanoma by detecting the presence of at least one mutation in GRM3 and administering an appropriate therapy. Further provided are methods of selecting a subject diagnosed with melanoma as a candidate for treatment with a GRM3 inhibitor, an MEK inhibitor, or both, by detecting the presence of at least one mutation in GRM3.07-25-2013
20130190372BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.07-25-2013
20090312383Fused Heterocyclic Compounds - There is provided a CRF receptor antagonist comprising a compound of the formula (I):12-17-2009
20100063122NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES - The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.03-11-2010
20110098329CATALYZED CARBONYLATION IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS - One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.04-28-2011
20110152336COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.06-23-2011
20090030058TOSYLATE SALT OF 6- (4-BR0M0-2-CHL0R0PHENYLAMIN0) -7-FLUORO-N- (2-HYDROXYETHOXY) -3-METHYL-3H-BENZIMI DAZOLE- 5 - CARBOXAMIDE , MEK INHIBITOR USEFUL IN THE TREATMENT OF CANCER - The present invention relates to a tosylate salt of Compound 1 and polymorphs thereof, in particular crystalline and amorphous forms of Compound 1 tosylate salt, and methods of preparation thereof. Pharmaceutical compositions containing these salts as active ingredient, their use in the manufacture of medicaments for use in the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body, and their use in methods for the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body are also described.01-29-2009
20090030057Pharmaceutical composition of telmisartan - The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%. At least one water insoluble diluent is preferred for use in the pharmaceutical composition in an amount from about 40% to about 70% of the total weight of the pharmaceutical composition. A preferred water insoluble diluent is microcrystalline cellulose. Also described are a pharmaceutical composition comprising telmisartan having a powder X-ray diffraction pattern, methods of preparing such pharmaceutical composition, and a crystalline form of Telmisartan.01-29-2009
20110178145ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OFINTRAOCULAR PRESSURE-LOWERING EFFECT - The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours.07-21-2011
20110160263Small molecule inhibition of PDZ-domain interaction - Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula (I) or (III). The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl), inhibiting Wnt signaling.06-30-2011
20130123316Bendamustine Pharmaceutical Compositions - The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.05-16-2013
20110263667SALTS OF ISOBUTYRIC ACID (1 R*,2R*,4R*) -2- (2- - ETHYL)-5-PHENYL-BICYCLO [2.2.2] OCT-5-EN-2-YL - The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.10-27-2011
20110118324METHOD AND COMPOSITION FOR TREATING MULTIPLE SCLEROSIS (VARIANTS) - The invention relates to psychoneurology, more particularly to a method for treating multiple sclerosis that involves the use of a pharmaceutical composition containing 1,3-diethylbenzimidazole triiodide as the active compound. The composition (in solid or liquid form) for treating multiple sclerosis contains 1,3-diethylbenzimidazole triiodide and medicinal low-molecular polyvinylpyrrolidone and also, in the liquid form, ethyl alcohol in the following component ratio: liquid form—1.5-10.0 mass % 1,3-diethylbenzimidazole triiodide, 6.0-30.0 mass % medicinal low-molecular polyvinylpyrrolidone and 60.0-92.5 mass % 95% ethyl alcohol; solid form—10.0-25.0 mass % 1,3-diethylbenzimidazole triiodide and 75.0-90.0 mass % medicinal low-molecular polyvinylpyrrolidone.05-19-2011
20100298396MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR - Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.11-25-2010
20090209606Cancer Treatments - Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such treatments are also provided.08-20-2009
20110190364BENZIMIDAZOLE MODULATORS OF VR1 - The invention is directed to compounds of Formula (I):08-04-2011
20110190363LIQUID FORMULATIONS OF BENDAMUSTINE - Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.08-04-2011
20100022610New Crystalline Forms - A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a citric acid salt, a methanesulphonic acid salt, or a p-toluenesulphonic acid salt of said compound.01-28-2010
20100016394BIOCIDAL COMPOSITIONS - Provided are synergistic biocidal compositions. The compositions comprise diiodomethyltolylsulfone and methyl 2-benzimidazolecarbamate and optionally 1,3-dicyano-tetrachlorobenzene. The compositions are useful for controlling growth of microorganisms in a variety of applications, including in building materials such as wallboard panels.01-21-2010
20100016393NOVEL HYDROGEN SULFATE SALT - The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I01-21-2010
20100216858BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS - The present invention is directed to pharmaceutical compositions comprising: (a) bendamustine, (b) a charged cyclopolysaccharide, and (c) a stabilizing agent having a charge opposite to that of the cyclopolysaccharide. Such composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. Such compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.08-26-2010
20090170921Benzimidazole derivatives - A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof:07-02-2009
20110077280Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.03-31-2011
20120157505ORAL FORMULATIONS OF BENDAMUSTINE - The present invention is directed to oral formulations of bendamustine, and its pharmaceutically acceptable salts, methods of use thereof, and methods of treatment comprising them.06-21-2012
20100093818BENZIMIDAZOLE DERIVATIVES - The invention is concerned with novel benzimidazole derivatives of formula (I)04-15-2010
20120122944TETRAHYDRONAPHTHALENE DERIVATIVES - This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment:05-17-2012
20110184036FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.07-28-2011
20120129904Liquid Formulations Of Bendamustine - Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.05-24-2012
201002738504-HETEROARYL-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES - Compounds of Formula I: I in which D10-28-2010
20120190720Combination Therapy With Parp Inhibitors - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.07-26-2012
20120264795COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARD inhibitors in combination with temozolomide (TMZ).10-18-2012
20110237635TETRAHYDRONAPHTHALENE DERIVATIVES - This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment:09-29-2011
20120088807INTERLACED METHOD FOR TREATING CANCER OR A PRECANCEROUS CONDITION - The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G04-12-2012
20130018079ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF - Described herein is a novel class of inhibitors of bacterial cell division. Several lines of evidence suggest the compounds disclosed herein specifically target the division process and have antibacterial activity in vitro and in vivo. The inhibitors are useful for treating subject in need of treatment for bacterial infections as will as for inhibiting bacterial growth, such as growth on contaminated surfaces.01-17-2013
20080227839Kinase Inhibitors - The present invention provides kinase inhibitors of Formula I:09-18-2008
20130143937CHLORTHALIDONE COMBINATIONS - The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension.06-06-2013
20090018177Propane-1,3-Dione Derivative or Salt Thereof - Compounds useful as GnRH receptor antagonists are provided. The present inventors have further examined propane-1,3-dione derivatives and confirmed as a result that a propane-1,3-dione having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene), or a compound which has benzene or thiophene ring substituted with a group derived from 1-hydroxymethyl, shows excellent availability, in addition to its excellent GnRH receptor antagonism, thereby accomplishing the invention. Since the compound of the invention shows excellent availability, in addition to its strong GnRH receptor antagonism, it can be expected that it exerts superior drug effect in the living body, and it is useful for the treatment of sex hormone dependent diseases such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy and the like. In addition, since the compound of the invention is excellent in metabolic stability in human and also is less in drug interaction, it has more desirable properties as a medicament to be used for the aforementioned diseases.01-15-2009
201102698062-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS - The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.11-03-2011
20130131131Bendamustine Pharmaceutical Compositions - The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.05-23-2013
20120277277Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal - Disclosed are methods for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals, comprising administering to a mammal in heed thereof a pharmaceutical composition comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an anti-tumour agent or in combination with radiation therapy.11-01-2012
20130158089MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR - Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:06-20-2013
20130190373ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS - A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.07-25-2013
20120015995BENDAMUSTINE ANIONIC-CATIOINIC CYCLOPOLYSACCHARIDE COMPOSITIONS - The present invention is directed to pharmaceutical compositions including: (a) bendamustine, (b) a first charged cyclopolysaccharide, and (c) a stabilizing agent which is a second charged cyclopolysaccharide having a charge opposite to that of the first charged cyclopolysaccharide. The composition provides unexpectedly desirable stability in reactive environments such as plasma, coupled with unexpectedly desirable anticancer activity. The compositions are suitable for injection or infusion into patients in need for treatment with bendamustine.01-19-2012
20130210878BENDAMUSTINE COMPOSITIONS AND METHODS THEREFORE - Aqueous Bendamustine formulations with improved stability are disclosed. Especially preferred formulations are low-dose ready-to-use liquid formulations in which Bendamustine is in a non-aqueous vehicle in combination with an aqueous phase that contains significant quantities of chloride.08-15-2013
20130210879FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid contains a mixture of PEG and PG; an organic or inorganic compound in an amount sufficient to obtain a pH of from about 6.0 to about 11 for the polyethylene glycol, as measured using USP monograph for polyethylene glycol; and optionally an antioxidant. The bendamustine-containing compositions have less than about 5% total esters, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.08-15-2013

Patent applications in class Benzo fused at 4,5-positions of the diazole ring

Patent applications in all subclasses Benzo fused at 4,5-positions of the diazole ring